0000000000179712

AUTHOR

G Casetta

showing 2 related works from this author

Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

2011

Objectives: Nomograms are statistical models designed to maximize predictive accuracy. We have tested the statistical correlation between the predictions of International Bladder Cancer Nomogram Consortium and the clinical outcomes in a multicenter Italian cohort of patients treated with radical cystectomy (RC) and pelvic lymph-nodes dissection. Methods and materials: Two hundred four patients who underwent RC were selected for multiple variable and then enrolled in the study. Patients were tested by the "online tool" based on the nomogram, then stratified and risk grouped for 5-year predicted disease-free survival (pDFS): low risk (67%-100%), intermediate risk (34%-66%), and high risk grou…

Malemedicine.medical_treatmentKaplan-Meier EstimatePostoperative nomogramNomogramCohort StudiesRetrospective StudieArea under curvePostoperative Periodinvasive bladder cancer; Postoperative nomogramAged 80 and overSettore MED/24 - UROLOGIAinvasive bladder cancerMiddle AgedPrognosisOncologyArea Under CurveUrinary Bladder NeoplasmCohortFemaleHumanCohort studyAdultmedicine.medical_specialtyPrognosiUrologyUrologyCystectomyDisease-Free SurvivalCystectomymedicineHumansAgedNeoplasm StagingRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryRetrospective cohort studyNomogrammedicine.diseaseRadical cystectomyNomogramsROC CurveUrinary Bladder NeoplasmsCohort StudieNeoplasm GradingPredictionbusinessStatistical correlationUrologic oncology
researchProduct

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-…

2004

Abstract Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses…

MaleCancer Researchmedicine.medical_specialtyUrologyAdministration OralPhases of clinical researchVinblastineMetastasisClinicalProstate cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousSurvival analysishormone-escaped prostate cancerEMP/VBL vs EMPbusiness.industryProstatic NeoplasmsCombination chemotherapyProstate-Specific Antigenmedicine.diseaseSurvival AnalysisPhase IISurgeryVinblastineProstate-specific antigenOncologyDrug Resistance NeoplasmDisease ProgressionEstramustineEstramustinebusinessmedicine.drug
researchProduct